Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bial Pharmaceuticals
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.
- Generic Drugs
- Other Names / Subsidiaries
- Bial – Portela & C.ª S.A.